Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:GEMDCVE:GGINYSE:HSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMDGoldman Sachs Access Emerging Markets USD Bond ETF$40.98+1.7%$40.25$38.37▼$42.69$28.19M0.5311,277 shs6,921 shsGGIGaribaldi ResourcesC$0.07-7.1%C$0.07C$0.05▼C$0.10C$8.94M0.550,581 shs50,000 shsHSPHospira$0.00$0.00▼$0.00N/AN/AN/AN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMDGoldman Sachs Access Emerging Markets USD Bond ETF0.00%+0.38%+1.94%+2.94%+1.12%GGIGaribaldi Resources0.00%-7.14%+8.33%+18.18%-35.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AGGIGaribaldi ResourcesN/AN/AN/AN/AN/AN/AN/AN/AHSPHospiraN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMDGoldman Sachs Access Emerging Markets USD Bond ETF 0.00N/AN/AN/AGGIGaribaldi Resources 0.00N/AN/AN/AHSPHospira 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AN/AN/AN/AN/AN/AGGIGaribaldi ResourcesN/AN/AC$0.00 per share17.31C$0.29 per shareN/AHSPHospiraN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AN/A0.00∞N/AN/AN/AN/AN/AGGIGaribaldi Resources-C$956.85K-C$0.01N/A∞N/AN/A-2.41%-1.35%N/AHSPHospiraN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMDGoldman Sachs Access Emerging Markets USD Bond ETF$2.626.39%N/AN/AN/AGGIGaribaldi ResourcesN/A4.63%N/AN/AN/AHSPHospiraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AN/AN/AGGIGaribaldi ResourcesN/A0.021.51HSPHospiraN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AGGIGaribaldi ResourcesN/AHSPHospiraN/AInsider OwnershipCompanyInsider OwnershipGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/AGGIGaribaldi Resources24.60%HSPHospiraN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGEMDGoldman Sachs Access Emerging Markets USD Bond ETFN/A700,000N/ANot OptionableGGIGaribaldi ResourcesN/A137.50 millionN/ANot OptionableHSPHospiraN/AN/AN/ANot OptionableGEMD, OKU, GGI, AFRK, and HSP HeadlinesRecent News About These CompaniesBiosimilar junket: Hospira took UK pharmacists to 5-star hotel in CroatiaNovember 20, 2024 | pharmaphorum.comPHow to quiet the noise in your head, and feel happier at work and in lifeOctober 23, 2024 | msn.comHenoch-Schonlein Purpura in an AdultAugust 29, 2024 | medscape.comMNLNG Partners More Health Institutions As Part Of Hospital Support ProgrammeApril 18, 2024 | leadership.ngLHanoi Synthetic Paint JSC HSPApril 16, 2024 | morningstar.comMMooney legal fund accepts donation from company at center of ethics investigationDecember 21, 2023 | weirtondailytimes.comWPlum A+ Infusion System from HospiraOctober 31, 2023 | news-medical.netNMental health coaching can help bridge the gap in provider shortage in KansasOctober 6, 2023 | msn.comBumi Armada restores FPSO in UKAugust 10, 2023 | thestar.com.myTMOM introduces new measures for workplace safety as HSP endsMay 31, 2023 | sbr.com.sgSISMP Survey Reveals User Issues With Carpuject Prefilled SyringesMay 11, 2023 | medscape.comMThe ‘missing personality type’: could you be a Highly Sensitive Person?April 20, 2023 | theguardian.comHannah Waddingham recalls daughter’s 'horrific' health scare: What is Henoch-Schönlein purpura (HSP)?April 3, 2023 | uk.style.yahoo.comHealthLynked awarded patent for "Secure Patient Access via Healthcare Service Provider Specific Wireless Access Point”March 21, 2023 | proactiveinvestors.comPfizer's $17bn Hospira acquisition paves way for break upMarch 14, 2023 | pharmaphorum.comPLifeCare PCA Infusion System from HospiraMarch 1, 2023 | news-medical.netNThose who invested in Hargreaves Services (LON:HSP) three years ago are up 65%February 11, 2023 | yahoo.comHospira Stock Falls On Unusually High Volume (HSP)February 10, 2023 | thestreet.comBeing a Highly Sensitive Person Is a Scientific Personality Trait. Here’s What It Feels Like.January 23, 2023 | healthline.comHWhat Is Paraparesis and How Is It Treated?January 21, 2023 | healthline.comHNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleGEMD, OKU, GGI, AFRK, and HSP Company DescriptionsGoldman Sachs Access Emerging Markets USD Bond ETF BATS:GEMD$40.98 +0.68 (+1.67%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Goldman Sachs Access Emerging Markets USD Bond ETF (GEMD) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund tracks a market value-weighted index of USD-denominated emerging markets government bonds of various credit quality and maturity. Bonds are selected by multiple economic factors such as governance indicators, import coverage, and inflation. GEMD was launched on Feb 15, 2022 and is managed by Goldman Sachs.Garibaldi Resources CVE:GGIC$0.06 -0.01 (-7.14%) As of 07/4/2025 09:30 AM EasternGaribaldi Resources Corp., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral properties in Canada and Mexico. The company explores for nickel, copper, cobalt, platinum, palladium, gold, and silver deposits. Its flagship property is 100% owned E&L Nickel Mountain Project located to Northwest British Columbia. The company was incorporated in 1993 and is headquartered in Vancouver, Canada.Hospira NYSE:HSPHospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
